Bristol Myers Squibb announced AstraZeneca’s Cristian Massacesi as new CMO, following a period of transformative oncology portfolio growth and pipeline expansion. Massacesi brings extensive experience shaping oncology drug development at global pharmaceutical leaders, positioning BMS to navigate looming patent expirations and competitive challenges in key franchises. Organizational shifts also include Thermo Fisher Scientific, Agilent Technologies, and other biotech companies announcing executive changes, reflecting ongoing leadership realignments in the industry.